265 related articles for article (PubMed ID: 11472706)
1. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
McKenney JM; McCormick LS; Schaefer EJ; Black DM; Watkins ML
Am J Cardiol; 2001 Aug; 88(3):270-4. PubMed ID: 11472706
[TBL] [Abstract][Full Text] [Related]
2. Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
Insull W; Toth PP; Superko HR; Thakkar RB; Krause S; Jiang P; Parreno RA; Padley RJ
Vasc Health Risk Manag; 2010 Nov; 6():1065-75. PubMed ID: 21191426
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
[TBL] [Abstract][Full Text] [Related]
4. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
[TBL] [Abstract][Full Text] [Related]
5. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
Bays HE; McGovern ME
Prev Cardiol; 2003; 6(4):179-88. PubMed ID: 14605511
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
McKenney JM; McCormick LS; Weiss S; Koren M; Kafonek S; Black DM
Am J Med; 1998 Feb; 104(2):137-43. PubMed ID: 9528731
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
Pontrelli L; Parris W; Adeli K; Cheung RC
Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170
[TBL] [Abstract][Full Text] [Related]
9. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern.
O'Keefe JH; Captain BK; Jones PG; Harris WS
Prev Cardiol; 2004; 7(4):154-60. PubMed ID: 15539961
[TBL] [Abstract][Full Text] [Related]
11. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
[TBL] [Abstract][Full Text] [Related]
12. The effects of niacin on lipoprotein subclass distribution.
Morgan JM; Carey CM; Lincoff A; Capuzzi DM
Prev Cardiol; 2004; 7(4):182-7; quiz 188. PubMed ID: 15539965
[TBL] [Abstract][Full Text] [Related]
13. Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype.
Xu RX; Guo YL; Li XL; Li S; Li JJ
Clin Exp Pharmacol Physiol; 2014 Jul; 41(7):475-81. PubMed ID: 24739131
[TBL] [Abstract][Full Text] [Related]
14. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JA; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2002 Oct; 90(7):689-96. PubMed ID: 12356379
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
16. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
Soedamah-Muthu SS; Colhoun HM; Thomason MJ; Betteridge DJ; Durrington PN; Hitman GA; Fuller JH; Julier K; Mackness MI; Neil HA;
Atherosclerosis; 2003 Apr; 167(2):243-55. PubMed ID: 12818407
[TBL] [Abstract][Full Text] [Related]
17. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
Diabetes Atorvastin Lipid Intervention (DALI) Study Group
Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
[TBL] [Abstract][Full Text] [Related]
18. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
Alaupovic P; Heinonen T; Shurzinske L; Black DM
Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
[TBL] [Abstract][Full Text] [Related]
19. Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?
Bays H; Conard S; Leiter LA; Bird S; Jensen E; Hanson ME; Shah A; Tershakovec AM
Lipids Health Dis; 2010 Nov; 9():136. PubMed ID: 21118495
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.
Karalis DG; Ross AM; Vacari RM; Zarren H; Scott R
Am J Cardiol; 2002 Mar; 89(6):667-71. PubMed ID: 11897207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]